About
Multiple Myeloma is a cancer characterized by the proliferation of a clone of plasma cells in the bone marrow and induces overproduction of immunoglobulins (antibody proteins) that crowd out the normal blood-forming cells and prevent them from functioning effectively.
The symptoms of Multiple Myeloma include bone lesions, anaemia, kidney damage and susceptibility to infections. Patients commonly experience bone pain and fractures, also experiencing weight loss, tiredness and repeated infections(2).
The tumour plasma cell clone proliferation induces high levels concentration of Monoclonal protein (also called M-Protein) which is the best tumour markers of the disease.
Diagnosis
Serum and urine protein electrophoresis and their immunological characterisation are the gold standard for Multiple Myeloma diagnosis, for monitoring the disease and to assess the patient’s response to treatment.
Protein electrophoresis is recommended by IMWG (International Myeloma Working Group) for screening serum and urine samples for abnormalities protein detection(3).
Once the Monoclonal protein is identified (or suspected), it must be characterized by an immunofixation or immunotyping test to identify the M-Protein type (IgG, IgA, IgM, IgD, IgE) and light chain (kappa or Lambda) involved.
Sebia’s Expertise
Sebia is the world leader in diagnosis and monitoring of Multiple Myeloma patient by offering a full range of solutions to enable clinicians to provide optimal medical care. Ensuring high quality results adapted to all laboratories sizes. Sebia solutions offer serum and urine proteins electrophoresis (SPE/UPE) for screening and identification (immunofixation/Immunotyping), measurement of FLC* and follow-up monoclonal antibody therapy with HYDRASHIFT portfolio.
* Under Product Registration approval
Featured resources on Multiple Myeloma
See all resourcesHYDRASHIFT avoids monoclonal antibody interference on IMMUNOFIXATION
The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.
Complete your Myeloma diagnostic tools with Sebia FLC Assay
The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.
Discover how the automation track integration boosted the high potential of CAPILLARYS 3
With this short video report, become aware of all the benefits of partnering with Sebia and integrate your capillary electrophoresis into the lab track automation.
Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab
Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.
Multiple Myeloma clinical cases for diagnosis and monitoring according to latest IMWG recommendations
Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD
Performance of Immunotyping vs. Immunofixation for the Detection of Monoclonal Gammopathies
Educational Webinar with Katie Thoren, PhD, Memorial Sloan Kettering Cancer Center
AL Amyloidosis: Role of clinical lab in diagnosis and management
Educational Webinar with Prof. Giovanni PALLADINI, PhD
Early detection of Multiple Myeloma: The importance of serum protein electrophoresis
Educational Webinar with Dr. Julien GUILLEMAUD
Challenges in Implementing Capillary Electrophoresis for Immunotyping
Educational Webinar with Dr. Jack Maggiore from Loyola University Medical Center in Chicago, IL
Clinical use of FLC testing in Multiple Myeloma and AL Amyloidosis
Educational Workshop with Pr Giovanni Palladini
HYDRASYS 2 SCAN FOCUSING: Overview
Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.
Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Upcoming events
See all events
MINICAP FLEX-PIERCING
The compact and affordable automation of Capillary Electrophoresis.
CAPILLARYS 3 TERA MC
The power of up to 36 capillaries in one automated high volume workcell.
CAPILLARYS 3 TERA TLA
Connect our flexible electrophoresis instrument on lab automation track.
CAPILLARYS 3 OCTA
Evolution makes the difference.
Serum Protein by Capillary Electrophoresis
High throughput Serum Protein Electrophoresis, with high resolution results.
Urine Protein by Capillary electrophoresis
High throughput Urine Protein Electrophoresis, with high resolution results.
Serum and Urine Immunofixation
Identification of monoclonal proteins by agarose gel electrophoresis.
Serum and Urine Immunotyping
Fully automated monoclonal proteins identification by Capillarys electrophoresis.
Free Light Chains* (FLC)
The next generation Free Light Chain Assay.
* Under Product Registration approval
HYDRASHIFT
Avoid interferences due to therapeutic Monoclonal Antibody with HYDRASHIFT Portfolio.
(1) https://www.cancerresearchuk.org
(2) https://www.mayoclinic.org/
(3) https://www.myeloma.org/international-myeloma-working-group
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.